Pharmacologic management of nocturnal polyuria: a contemporary assessment of efficacy, safety, and progress toward individualized treatment

Thomas F. Monaghan, Jeffrey P. Weiss, Karel Everaert and Alan J. Wein

Abstract: This narrative review synthesizes current evidence on the medical management of nocturnal polyuria, including antidiuretic replacement therapy as well as other emerging modalities, with particular emphasis on areas of active investigation and future research directions. Relative to earlier formulations, the pharmacological profiles of novel desmopressin acetate nasal spray and orally disintegrating tablet formulations appear favorable in optimizing the balance between efficacy and safety. Additionally, several highly selective small-molecule arginine vasopressin 2 receptor agonists are under active development, while appropriately timed short-acting diuretics, pharmacotherapy for hypertension, nonsteroidal anti-inflammatory drugs, and sex hormone replacement therapy are also a focal point of extensive ongoing nocturnal polyuria research. Emerging laboratory technologies now make feasible a sub-stratification of nocturnal polyuria patients into substrate-based phenotypes for individualized treatment. An increasingly refined understanding of the pathogenesis of nocturnal polyuria, and arginine vasopressin dysregulation in particular, has also introduced new opportunities for point-of-care testing in patients with nocturnal polyuria.

Keywords: AVP, diuretics, estrogen, furosemide, hypertension, vasopressin

Introduction
Nocturia is one of the most common and bothersome lower urinary tract symptoms (LUTS) in the general population.\(^1,2\) Nocturia is associated with significant morbidity, having been identified as an age-independent risk factor for falls and hip fractures, direct mediator of poor sleep, and prognostic factor for all-cause mortality.\(^3-5\) The pathogenesis of nocturia is multifactorial,\(^6\) but medical therapy is frequently a staple of treatment, particularly in the absence of identifiable contributory comorbidities or behavioral factors – as is often the case in the real-world outpatient urology setting.\(^8,9\) Historically, pharmacotherapy for nocturia centered on agents directed at lower urinary tract dysfunction, such as those commonly used in the treatment of benign prostatic hyperplasia (BPH) and overactive bladder syndrome (OABS). Problematically, agents for BPH and OABS often fail to treat the primary pathophysiology of nocturia and, thus, inconsistently translate to meaningful benefit for patients in the real-world clinical setting.\(^10-12\) However, several recent advancements in pharmacotherapy for nocturnal polyuria – the most common cause of nocturia in adults of all ages and backgrounds – have the potential to reshape management and raise the standard of care for patients suffering from nocturia.\(^13,14\) Accordingly, this narrative review aims to synthesize available evidence on the efficacy and safety of current pharmacotherapies, as well as...
as and progress toward individualized treatment for patients with nocturnal polyuria.

**Antidiuretic replacement therapy**

**Mechanism**
Desmopressin (1-deamino-8-D-arginine vasopressin) is a synthetic analog of endogenous arginine vasopressin (AVP), a neuropeptide that is produced most abundantly by the supraoptic and paraventricular nuclei of the hypothalamus, transported to terminals of the posterior pituitary gland, and released into the general circulation in response to osmotic stimuli. AVP release in response to hyperosmolality plays a central role in physiologic water homeostasis by regulating water conservation at the level of the kidneys. Binding of AVP to the V2 receptor subtype (AVPR2) in the epithelial layer of renal collecting tubules promotes trafficking of aquaporin-2 integral membrane proteins to the apical plasma membrane surface to increase water permeability, facilitating water reabsorption and dilution of extracellular fluid, thereby concentrating the urine.

Endogenous AVP is normally expected to rise across the hours of sleep, promoting free water conservation and decreasing nocturnal urine volume, which naturally counteracts bladder filling and subsequent urge-driven nocturnal awakenings. Therefore, a blunted physiologic rise in nocturnal AVP secretion, as has been observed in some nocturnal polyuria study samples, lends to excess nocturnal water diuresis and increased nocturnal urine production. Mechanistically, the primary role of antidiuretic replacement therapy in alleviating nocturia is thus accomplished via a significant reduction in nocturnal water diuresis.

**Early formulations and endpoints**
In healthy patients, the act of sleeping through the night without urinating requires that the nocturnal urine volume not exceed functional bladder storage capacity. When nocturnal urine volume does exceed the functional storage threshold – nocturia if the sensation of bladder fullness causes the patient to awaken and, if not, enuresis must ensue. Further, in view of the mechanism of action of antidiuretic replacement therapy, the primary role of desmopressin in alleviating both nocturia and nocturnal enuresis is accomplished via a significant reduction in nocturnal water diuresis.

Correspondingly, initial trials of desmopressin in patients with nocturia employed oral tablet doses with proven efficacy in the treatment of monosymptomatic nocturnal enuresis (100–400 mcg).

Despite the congruence between the pathogenesis and expected mechanism of treatment response between nocturia and nocturnal enuresis, there were several pertinent methodological differences between enuresis and nocturia trials, as well as other fundamental distinctions between these two entities seemingly not accounted for in the dosing schema for nocturia. The standard primary outcome variable in trials of desmopressin for primary monosymptomatic nocturnal enuresis was change in the frequency of wet nights. In view of the production-storage mismatch central to the pathogenesis of nocturnal micturition, a binary treatment outcome (i.e., “dry night” or “wet night” in enuretic children) requires maximal suppression of nocturnal urine production to a level below the functional storage threshold. Among adults with nocturia, the analogous outcome would be complete symptom resolution (i.e., zero nocturnal voids), which was indeed the criterion for “full response” in the dose titration phase of early pivotal trials for nocturia. While complete resolution of nocturia (without adverse events) would indeed reflect the optimal response to treatment for nocturia, the number of nightly voids is associated positively with nocturia-related impairments in quality of life, such that nocturia severity has been increasingly described to exist on a graded continuum. Current understanding of nocturia as a continuous measure is of direct clinical relevance because treatment that successfully reduces nocturnal voiding frequency is associated with significant improvements in overall health-related quality of life – even in patients who do not experience complete symptom resolution.

Many of the consequences of nocturia on health-related quality of life have been increasingly recognized to be mediated by the direct adverse effects of nocturia on sleep outcomes. Multiple studies have implicated nocturia as the most common cause of nocturnal awakenings in adults and most patients with nocturia experience their first nocturnal voiding episode within the first 2–3h of sleep. This time period is particularly meaningful because it coincides with the greatest concentration of slow-wave (i.e., N3 or “deep”) sleep in the normal sleep cycle. Slow-wave sleep,
which is clustered toward the beginning of the
night, is considered the most restorative stage
of sleep. Disrupted slow-wave sleep may not be
recovered later in the night upon return to sleep
and independently contributes to significant
daytime fatigue and discomfort, even when sleep effi-
ciency and total sleep duration are preserved. Patients
with nocturia demonstrate an inverse relationship between the total number of noctur-
mal voids and the duration of time from sleep
onset until the first nocturnal awakening to void
[i.e., first uninterrupted sleep period (FUSP)]. Consistently, a shorter FUSP is associated with
lower whole-night sleep quality, sleep efficiency,
and total sleep duration, corresponding to signifi-
cant impairment in daytime function. Furthermore, improvement in the actual number of nocturnal voids is accompanied not only by a
prolongation in the FUSP, but also in the total
duration of sleep and overall sleep quality. Treatment aimed at extending FUSP in particu-
lar may be central to mitigating the vast deleteri-
ous sequelae of nocturia, as was exemplified in a
recent study of blood sugar in nocturia patients,
which reported significant improvement in blood
sugar upon successful prolongation of FUSP.

Consideration of more refined clinical endpoints,
with a particular emphasis on graded treatment
response, sleep, and the broader sequelae of noc-
turia, has facilitated a more holistic approach to
nocturia evaluation and management. By the
same token, there now exist several lines of evi-
dence to suggest that the optimal dose range of
desmopressin for nocturia may actually lie below
the dose range initially surmised from the man-
agement of enuresis. While the pharmacokinetics
of desmopressin are comparable between chil-

Desmopressin acetate nasal spray
In March 2017, desmopressin acetate nasal spray
became the first desmopressin formulation to be
approved by the US Food and Drug
Administration (FDA) in the treatment of noc-
turia, indicated for patients with nocturnal polyu-
ria who void ≥2 times nightly. Desmopressin
acetate nasal spray is an intranasal formulation of
desmopressin with cyclopentadecanolide (CPD) – a novel cyclic fatty acid excipient designed to
improve permeation, enhancing absorption across
the nasal mucosa and bioavailability of the active
compound. The proposed advantages of this
formulation include potentially more consistent
and predictable dosing, more rapid onset of the
drug effect, and decreased likelihood of prolonged
drug activity. In doses of 0.83 mcg and 1.66 mcg per 0.1 ml nasal
spray, bioequivalent to 0.75 mcg and 1.5 mcg
desmopressin free base per spray, respectively. The 1.66 mcg/0.1 ml dosage is recommended for
patients <65 years without risk factors for hypona-
tremia, whereas patients ≥65 years or at increased
hyponatremia risk should be started at the
0.83 mcg/0.1 ml dose, and, if needed, advanced to
1.66 mcg/0.1 ml after 1 week provided that serum
sodium remains within normal limits. Patients
should be instructed to administer one spray in
either nostril approximately 30 min prior to
bedtime. Consistent with other desmopressin
products, the main safety finding with this agent is hyponatremia, which can be mitigated by following warnings and precautions outlined in the prescribing information as well as scheduled serum sodium monitoring. Serum sodium should be measured before treatment, within 7 days and approximately 1 month after initiation or dose escalation, and then periodically during treatment, with more frequent monitoring in patients ≥65 years or at increased risk of hyponatremia.

FDA approval for desmopressin acetate nasal spray was based on data from two independent North American phase III double-blind randomized placebo-controlled trials [ClinicalTrials.gov identifiers: NCT01357356 and NCT01900704] of patients ≥50 years of age with ≥2 nightly voids for more than 6 months and ≥2.16 average nightly voids during a 2-week screening period (Table 1). Eligible patients were randomized equally to receive 1.66 mcg/0.1 ml or 0.83 mcg/0.1 ml (or 1.11 mcg/0.1 ml in one of the studies only) or placebo for 12 weeks. Co-primary endpoints were mean change in nocturia frequency and the percentage of patients reporting a ≥50% response in nocturia frequency, as determined from nighttime voiding diaries maintained for three consecutive nights, which were completed by participants at baseline and then 1, 2, 4, 6, 8, 10, and 12 weeks post-randomization. Secondary endpoints were duration of the FUSP, percentage of nights with ≤1 or 0 nocturnal voids, change in nocturnal urine volume, and impact on quality of life [as assessed by validated questionnaire (one study only)]. Safety was assessed based on the incidence of adverse events, physical examination and electrocardiogram, and serum sodium monitoring at baseline and then at 2-week intervals post-randomization.

On pooled intent-to-treat analysis (n=1333), both doses of desmopressin acetate nasal spray conferred significant benefit compared with placebo for mean change in nocturia frequency [−1.4 with 0.83 mcg/0.1 ml and −1.5 with 1.66 mcg/0.1 ml compared with −1.2 with placebo (p<0.0001 for both)] as well as ≥50% response rate [37.9% with 0.83 mcg/0.1 ml and 48.7% with 1.66 mcg/0.1 ml compared with 30.3% with placebo (p=0.0227, p<0.0001, respectively)]. Additionally, both doses also conferred significant benefit compared with placebo in change in FUSP duration [+96 min with 0.83 mcg/0.1 ml and +108 min with 1.66 mcg/0.1 ml compared with +72 min with placebo (p=0.0121, p<0.0001, respectively)], and statistical significance was observed for all other secondary endpoints. A total of 5.9% of all patients discontinued the study due to adverse events, with study drug-induced adverse events observed in 3.5% of patients receiving 0.83 mcg/0.1 ml, 5.6% receiving 1.66 mcg/0.1 ml, and 4.0% receiving placebo. Upper respiratory symptoms (e.g., nasal discomfort, congestion, rhinorrhea, sinus pain, or throat irritation) were the adverse event most commonly leading to study discontinuation. The incidence of hyponatremia, defined as serum sodium ≤125 mmol/l or <130 mmol/l with symptoms, was 1.1% with 1.66 mcg/0.1 ml, 0% with 0.83 mcg/0.1 ml, and 0.2% with placebo. Differences in other adverse events were similar across treatment groups. Treatment efficacy was maintained with no overall changes in the safety profile at follow up of up to 2 years.

Desmopressin acetate orally disintegrating tablets

The FDA approved desmopressin acetate orally disintegrating tablets in June 2018, indicated for patients with nocturnal polyuria who void ≥2 times nightly. Orally disintegrating tablets are unique in that they are offered at sex-specific dosages, thus facilitating individualized treatment. Orally disintegrating tablets are available in doses of 27.7 mcg and 55.3 mcg, equivalent to 25 mcg and 50 mcg of desmopressin, respectively. The desmopressin 25 mcg tablets are recommended for women and the desmopressin 50 mcg tablets are recommended for men. Patients should be instructed to administer one tablet sublingually without water 60 min before bedtime. Consistent with other desmopressin products, the main safety finding with this agent is hyponatremia, which can be mitigated by following warnings and precautions outlined in the prescribing information for orally disintegrating tablets as well as scheduled serum sodium monitoring. Serum sodium should be measured before treatment, within 7 days and approximately 1 month after initiating treatment, and then periodically during treatment, with more frequent monitoring in patients ≥65 years or at increased risk of hyponatremia.

Foundational evidence regarding the efficacy and safety of orally disintegrating tablets has been derived from three independent multicenter phase III double-blind randomized placebo-controlled trials involving both men and women [ClinicalTrials.gov identifier: NCT00477490],
| Study                  | Study population                                                                 | Sample size | Treatment                                                                                                                   | Control                              | Endpoints                                                                                     | Outcomes                                                                 |
|-----------------------|-----------------------------------------------------------------------------------|-------------|-----------------------------------------------------------------------------------------------------------------------------|--------------------------------------|-----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Kaminetsky et al.59    | Adults with ≥50 years with ≥2 nocturnal voids [Pooled analysis of 2 independent North American studies] | 1333        | Desmopressin acetate nasal spray, 1.66 mcg/0.1 ml or 0.83 mcg/0.1 ml, 12 weeks                                           | Placebo, nasal spray, 12 weeks       | **Co-primary endpoints:** Change in nocturia frequency, 50% responder rate | **Co-primary endpoints:** Significant benefit in both co-primary endpoints with both dose levels |
|                       |                                                                                   |             |                                                                                                                            |                                      | Secondary endpoints: Change in FUSP duration, percentage of nights with ≤1 or 0 nocturnal voids, nocturnal urine volume, QoL [1 study only] | Secondary endpoints: Significant improvement in all secondary endpoints on pooled analysis with both dose levels; significant improvement in QoL with higher dose [1 study] |
|                       |                                                                                   |             |                                                                                                                            |                                      | Serum sodium monitoring: Baseline, every 2 weeks post-randomization | Hyponatremia: 1.1% with 1.66 mcg, 0% with 0.83 mcg, 0.2% with placebo [<125 mmol/l or <130 mmol/l with symptoms] |
| Weiss et al.24         | Adults with ≥2 nocturnal voids [US and Canada]                                    | 757         | Desmopressin, orally disintegrating tablet, 10, 25, 50 or 100 mcg, 4 weeks                                               | Placebo, orally, 4 weeks             | **Co-primary endpoints:** Change in average nocturia frequency, 33% responder rate | **Co-primary endpoints:** Significant benefit in change in nocturia frequency with 50, 100 mcg dose levels, 33% responder rate with 100 mcg* |
|                       |                                                                                   |             |                                                                                                                            |                                      | Secondary endpoints: Change in FUSP duration, nocturnal and 24-h urine volumes, QoL | Secondary endpoints: Significant improvement in FUSP duration and nocturnal urine volume with 25, 50, 100 mcg, 24-h volume with 100 mcg; significant improvement in QoL with each void reduced/hour of sleep gained |
|                       |                                                                                   |             |                                                                                                                            |                                      | Serum sodium monitoring: Baseline, day 4, day 8, weekly | Hyponatremia: <130 mmol/l in 3.0% of participants, <125 mmol/l in 1.1% [all observed within 1 week of treatment initiation] |
| Weiss et al.60         | Adult men with ≥2 nocturnal voids [US and Canada]                                 | 385         | Desmopressin, orally disintegrating tablet, 50 or 75 mcg, 12 weeks                                                    | Placebo, orally, 12 weeks           | **Co-primary endpoints:** Change in average nocturia frequency, 33% responder rate from baseline to final visit [longitudinal analysis] | **Co-primary endpoints:** Significant benefit in both co-primary endpoints with both dose levels |
|                       |                                                                                   |             |                                                                                                                            |                                      | Secondary endpoints: Change in average nocturia frequency and 33% responder rate at 3 months, FUSP duration, nocturnal urine volume | Secondary endpoints: Significant improvement in all secondary endpoints with both dose levels |
|                       |                                                                                   |             |                                                                                                                            |                                      | Serum sodium monitoring: At screening, day 4, week 1, months 1, 2, 3 | Hyponatremia: <130 mmol/l in 1.9% with 50 mcg, 1.9% with 75 mcg, 0% with placebo; <125 mmol/l in 1.9% with 50 mcg, 1.9% with 75 mcg, 0% with placebo |
| Sand et al.61          | Adult women with ≥2 nocturnal voids [US and Canada]                               | 261         | Desmopressin, orally disintegrating tablet, 25 mcg, 12 weeks                                                        | Placebo, orally, 12 weeks           | **Co-primary endpoints:** Change in average nocturia frequency, 33% responder rate from baseline to final visit [longitudinal analysis] | **Co-primary endpoints:** Significant benefit in both co-primary endpoints |
|                       |                                                                                   |             |                                                                                                                            |                                      | Secondary endpoints: Change in average nocturia frequency and 33% responder rate at 3 months, FUSP duration, nocturnal urine volume | Secondary endpoints: Significant improvement in change in nocturia frequency, FUSP duration, and nocturnal urine volume at 3 months; no difference in 33% responder rate at 3 months |
|                       |                                                                                   |             |                                                                                                                            |                                      | Serum sodium monitoring: During screening and all subsequent visits | Hyponatremia: <130 mmol/l in 2.2% with treatment, 0% with placebo; no instances of <=125 mmol/l in either group |

(Continued)
Table 1. (Continued)

| Study | Study population | Sample size | Treatment | Control | Endpoints | Outcomes |
|-------|------------------|-------------|-----------|---------|-----------|----------|
| Yamaguchi et al.62 | Adult men ⩾20years with bothersome nocturia (⩾2 nocturnal voids) and nocturnal polyuria** (Japan) | 342 [Mean age 63 ± 12.2 years] | Desmopressin, orally disintegrating tablet, 25 or 50 mcg, 12 weeks | Placebo, orally, 12 weeks | **Primary endpoint:** Change in average nocturia frequency from baseline to final visit **Secondary endpoints:** Change in FUSP duration, nocturnal urine volume, nocturnal polyuria index, QoL, sleep quality, bother **Serum sodium monitoring:** At screening, day 3, weeks 1, 2, 4, 8, 12 | Primary endpoint: Significant benefit with both dose levels **Secondary endpoints:** Significant improvement in FUSP duration, nocturnal urine volume, and nocturnal polyuria index with both dose levels; significant improvement in bother with 50 mcg, no difference in QoL or sleep quality **Hyponatremia:** <130 mmol/l in 0.9% with 25 mcg, 1.8% with 50 mcg, 0% with placebo; no instances of <125 mmol/l in any group |
| Yamaguchi et al.62 | Adult women ⩾20years with bothersome nocturia (⩾2 nocturnal voids) and nocturnal polyuria** (Japan) | 190 [Mean age 60 ± 12.8 years] | Desmopressin, orally disintegrating tablet, 25 mcg, 12 weeks | Placebo, orally, 12 weeks | **Primary endpoint:** Change in average nocturia frequency from baseline to final visit **Secondary endpoints:** Change in FUSP duration, nocturnal urine volume, nocturnal polyuria index, QoL, sleep quality, bother **Serum sodium monitoring:** At screening, day 3, weeks 1, 2, 4, 8, 12 | Primary endpoint: No statistically significant benefit versus placebo **Secondary endpoints:** Significant improvement in FUSP duration, nocturnal urine volume, and nocturnal polyuria index; no difference in QoL, sleep quality, bother **Hyponatremia:** No instances <130 mmol/l in either group |

*Several pertinent sex-based differences observed on post hoc analysis [see main text]. **Refractory to behavioral counseling and a 1-week placebo run-in period. FUSP, first uninterrupted sleep period [time from sleep onset until first nocturnal voiding episode]; QoL, quality of life; US, United States.

Although not factored into the primary study outcome post hoc analyses revealed several pertinent sex-based differences on the basis of sex. Among men, the 100 mcg dose conferred significant benefit compared with placebo for mean change in nocturia frequency [−1.38 with 100 mcg compared with −0.84 with placebo (p = 0.005)]. A total of 757 patients were included in the final intent-to-treat analysis. Among all patients, the 50 and 100 mcg doses conferred significant benefit compared with placebo for mean change in nocturia frequency [−1.18 with 50 mcg and −1.43 with 100 mcg compared with −0.86 with placebo (p = 0.020, p = 0.0001), respectively] and the 100 mcg dose conferred significant benefit for 33% responder rate [71% with 100 mcg compared with 47% with placebo (p < 0.0001)]. For secondary endpoints, change in nocturnal urine volume compared with placebo was significant with 25, 50, and 100 mcg doses, change in 24-h in total urine volume was significant with the 100 mcg dose, and change in duration of the FUSP was significant with 25, 50, and 100 mcg doses. In total, 24 (3%) of patients were found to have serum sodium levels <130 mmol/l, of whom 9 (1.1%) had reductions to <125 mmol/l.
well as for 33% responder rate [65% with 100 mcg compared with 50% with placebo (p=0.050)]. For secondary endpoints, change in nocturnal urine volume compared with placebo was significant with 50 and 100 mcg doses, change in 24-h in total urine volume was significant with the 100 mcg dose, and change in duration of the FUSP was significant with the 100 mcg dose. Among females, 25, 50, and 100 mcg doses conferred significant benefit compared with placebo for mean change in nocturia frequency [−1.22 with 25 mcg, −1.23 with 50 mcg, and −1.51 with 100 mcg compared with −0.88 with placebo (p=0.020, p=0.009, p < 0.0001, respectively)] as well as for 33% responder rate [62% with 25 mcg, 59% with 50 mcg, and 77% with 100 mcg compared with 42% with placebo (p=0.020, p=0.040, p < 0.0001, respectively)]. For secondary endpoints, change in nocturnal urine volume compared with placebo was significant with 10, 25, 50, and 100 mcg doses, change in 24-h in total urine volume was significant with the 25 mcg dose, and change in duration of the FUSP was significant with 25, 50, and 100 mcg doses.

This parallel study of men and women was particularly noteworthy in that it provided a pivotal foundation for establishing sex-specific dosing recommendations. These data from Weiss and colleagues, in conjunction with results from an open-label extension trial [ClinicalTrials.gov identifier: NCT00615836] and two separate phase I studies, were subsequently operationalized by Juul et al. to characterize sex differences in anti-diuretic response to desmopressin therapy.50 Juul and colleagues observed a significant sex difference in nocturnal urine volume with desmopressin, characterized by a significantly greater decrease (i.e., desmopressin sensitivity) with 10 and 25 mcg doses in women compared with men, which could not be explained by pharmacokinetic differences. Regarding tolerability, no hyponatremia events (defined as serum sodium <130 mmol/l) were identified in women ≤50 years old or men ≤65 years of age, but a dose-response relationship was observed in patients beyond 50 years of age, wherein the incidence of hyponatremia was approximately twofold greater in women at dose levels ≥25 mcg. Taken together, Juul et al. concluded that a dose of 50–100 mcg was optimal in balancing therapeutic benefit with tolerability in men, while a dose of 25 mcg is efficacious in women with no observed incidences of clinically significant hyponatremia. Notably, these findings were consistent with well-controlled physiologic evidence of sex differences in the endogenous regulation of AVP secretion and sensitivity,63 thought to be mediated by sex hormones or differential expression of AVPR2 receptor mRNA and protein on the X chromosome due to the process of X-inactivation in females.64–66

In view of growing evidence favoring sex-specific dosing for orally disintegrating tablets, Weiss et al. subsequently investigated the efficacy and safety of 50 mcg and 75 mcg orally disintegrating tablets compared with placebo in men ≥18 years with ≥2 voids nightly, as confirmed by 3-day voiding diary analysis during screening.60 Eligible patients underwent age-stratified equal randomization to receive 50 mcg or 75 mcg of desmopressin or placebo for 12 weeks. Co-primary endpoints were mean change in nocturia frequency and the percentage of patients reporting a mean change in average nocturia frequency of ≥33%, as determined from longitudinal analysis of 3-day voiding diaries, which were completed immediately pre- and post-randomization and then at weeks 1, 4, 8, and 12. Secondary endpoints were mean change in average nocturnal voiding frequency and ≥33% response rate at the 3-month mark, duration of the FUSP, and change in nocturnal urine volume. Safety was assessed based on the incidence of adverse events, physical examination with comprehensive blood and urine analyses, and serum sodium monitoring performed at baseline and then 4, 7, 30, 60, and 90 days after treatment initiation.

On final analysis (n=385), both doses of desmopressin acetate orally disintegrating tablets conferred significant benefit compared with placebo for adjusted mean change in nocturia frequency [−1.25 with 50 mcg and −1.29 with 75 mcg compared with −0.88 with placebo (p=0.0003, p < 0.0001, respectively)] as well as for adjusted odds of ≥33% response rate [odds ratio (OR) 1.98 with 50 mcg versus placebo; OR 2.04 with 75 mcg versus placebo (p=0.0009, p=0.004, respectively)]. Additionally, statistical significance was observed for secondary endpoints at 3 months, and both doses conferred significant benefit compared with placebo for change in FUSP duration [+112 min with 50 mcg and +116 min with 75 mcg compared with +73 min with placebo (p=0.006, p=0.003, respectively)]. The most common adverse events were dry mouth and headache, and a total of 4.7% of all patients experienced an adverse event leading to discontinuation. The incidence of hyponatremia
was 1.9% with 50 mcg, 3.3% with 75 mcg, and 0% with placebo using a serum sodium threshold of $\leq125\text{ mmol/l}$, and 1.9%, 7.4%, and 0%, respectively, using a serum sodium threshold of $<130\text{ mmol/l}.$

Contemporary to the desmopressin trial involving men, Sand et al. investigated the efficacy and safety of 25 mcg orally disintegrating tablets compared with placebo in women $\geq18$ years of age with $\geq2$ voids nightly, as confirmed by 3-day voiding diary analysis during screening. Core features of the study design, including randomization, primary and secondary outcomes, measurement and timing of outcomes, and safety monitoring, were analogous to those employed by Weiss and colleagues. On final analysis ($n=261$), desmopressin conferred significant benefit compared with placebo for adjusted mean change in nocturia frequency ($-1.46$ with desmopressin compared with $-1.24$ with placebo, $p=0.028$) as well as for adjusted odds of $\geq33\%$ improvement (OR $1.85$, $p=0.006$ compared with placebo). Statistical significance was also observed in the change in average nocturnal voiding frequency at the 3-month mark, as well as in the duration of the FUSP and nocturnal urine volume from baseline, although no significant difference was observed in 3-month 33% responder rate. The most common adverse events were urinary tract infection, headache, and upper respiratory tract infection, and a total of 1.9% of all patients experienced adverse events leading to discontinuation. The incidence of hyponatremia according using a serum sodium threshold $<130\text{ mmol/l}$ was 2.2% in the desmopressin group and 0% in the placebo group. No patients in either study arm were found to have serum sodium $\leq125\text{ mmol/l}.$

More recently, the concept of sex-specific dosing was also further explored through two independent multicenter phase III randomized placebo-controlled trials investigating orally disintegrating tablets in Japanese males [ClinicalTrials.gov identifier: NCT02904759] and females [ClinicalTrials.gov identifier: NCT02905682]. Patients $\geq20$ years of age were eligible if they were found to have persistent nocturia ($\geq2$ nocturnal voids) due to nocturnal polyuria after completing a 1-week placebo run-in period with behavioral counseling. Females received either 25 mcg or placebo and males received 25 mcg, 50 mcg, or placebo. The primary endpoint was change from baseline nocturnal voiding frequency during 12 weeks of treatment. Secondary endpoints included changes in duration of the FUSP, nocturnal urine volume, nocturnal polyuria index (defined as nocturnal urine volume/24-h urine volume), and nocturia-related quality of life. Safety was assessed based on the incidence of adverse events, physical examination with comprehensive blood and urine analyses, and serum sodium monitoring performed at baseline and then on days 3, 7, 14, 30, 60, and 90 after treatment initiation.

A total of 525 patients were included in the full analysis set. Among males ($n=338$), both 25 and 50 mcg dose levels conferred significant benefit in mean nocturia frequency compared with placebo ($-0.96$ with 25 mcg and $-1.21$ with 50 mcg compared with $-0.76$ with placebo ($p=0.0143$, $p<0.0001$, respectively). Among females ($n=187$), 25 mcg improved mean nocturia frequency with borderline statistical significance compared with placebo ($-1.11$ versus $-0.95$, respectively, $p=0.0975$). While the primary endpoint did not meet statistical significance according to conventional standards, duration of the FUSP, nocturnal urine volume, and nocturnal polyuria index all significantly improved beyond placebo for all dose levels in females as well as in males. Further, 25 mcg tablets in females, as well as 25 and 50 mcg tablets in males, demonstrated long-term efficacy and reasonable tolerability in a subsequent long-term trial designed partly as an extension study for subjects completing the phase III trials [ClinicalTrials.gov identifier: NCT03051009]. Treatment-emergent hyponatremia of $<130\text{ mmol/l}$ was observed in none of the females and in 0.9%, 1.8%, and 0% of males with 25 mcg, 50 mcg, and placebo, respectively. (Yamaguchi, Juul and Falahati, 2020) No patients of either sex were found to have serum sodium $\leq125\text{ mmol/l}.$ (Yamaguchi, Juul and Falahati, 2020)

**Sodium monitoring**

Owing to significant regional regulatory variation, current guidelines from the International Continence Society advocate for comprehensive monitoring when serum sodium checks are clinically warranted, but do not offer a consensus as to whether baseline serum sodium must be assessed before starting desmopressin in young patients with no risk factors for hyponatremia. However, more definitive recommendations have been detailed in current European Association of
Urology (EAU) guidelines for non-neurogenic male LUTS, as well as US FDA prescriber information for both desmopressin acetate nasal spray and orally disintegrating tablets. EAU guidelines specify that serum sodium should be assessed at the time of medication initiation or dose titration, and then 3, 7, and 30 days after baseline, followed by periodic monitoring across the course of treatment. According to these guidelines, maintenance serum sodium checks can be scheduled every 3 months for patients with stable serum sodium during the initial monitoring sequence, but should occur more frequently in patients ≥65 years or with risk factors for hyponatremia, and the initial monitoring regimen should be restarted following dose escalation. As outlined in the sections above, FDA prescriber information for both desmopressin acetate nasal spray and orally disintegrating tablets specifies safe use to include serum sodium monitoring for all patients prior to medication initiation, restart, or dose escalation, and again within 7 days and approximately 30 days from baseline, with subsequent periodic monitoring and more frequent checks in patients ≥65 years or at increased risk of hyponatremia. Indeed, the risk of hyponatremia in patients ≥65 is highlighted by the inclusion of desmopressin in the 2019 American Geriatrics Society Beers Criteria describing pharmaceuticals to be used with particular caution in both men and women of this age group.

Notwithstanding the logistical considerations of routine serum sodium monitoring, recent research contends that a conservative approach to sodium testing may reliably prevent clinically significant hyponatremia in patients on desmopressin replacement therapy. Using pooled data from 1443 patients included in phase III trials for desmopressin acetate orally disintegrating tablets, Juul et al. performed a meta-analysis to identify specific risk factors for clinically significant treatment-induced hyponatremia, defined as serum sodium <130 mmol/l. In both sexes, patient characteristics independently associated with significant hyponatremia included age ≥65 years and diminished renal clearance (<60 ml/min). Baseline serum sodium <135 mmol/l, as well as exposure to desmopressin above the sex-specific minimum effective dose (25 μg for females and 50 μg for men), were also identified as independent risk factors for clinically significant hyponatremia, and a majority of all hyponatremic events occurred within the first 3 weeks of treatment.

Consistent with these observations, Juul et al. devised a structured serum sodium monitoring plan for preventing desmopressin-induced hyponatremia. One approach proposed by the investigators called for a baseline serum sodium check in all patients, with repeat monitoring at 7 and 30 days in patients ≥65 years or concurrently taking other medications associated with hyponatremia. Notably, for patients exposed to the minimum effective dose of desmopressin, adherence to this sodium monitoring plan with immediate discontinuation following a serum sodium level <135 mmol/l would have successfully identified all subsequent cases of clinically significant hyponatremia for exclusion from further treatment. This particular sodium monitoring schedule was also noteworthy because of its significant overlap with current FDA prescriber guidelines for desmopressin (albeit slightly less stringent due to the researcher’s omission of 7- and 30-day repeat checks in healthy younger patients). While such analyses have not been repeated using desmopressin acetate nasal spray, nearly half the incident cases of serum sodium <130 mmol/l in pivotal trials for that formulation were likewise observed within the first 2 weeks following treatment initiation.

**Current trends in antidiuretic replacement therapy**

Based on a recent update from the EAU non-neurogenic male LUTS guidelines panel, desmopressin for nocturia in men <65 years is the only medication supported by Level 1a evidence, as well as the only specific pharmacotherapy to receive a Grade A recommendation in the treatment of nocturia. At present, real-world nocturnal polyuria patients are being actively recruited for long-term specified-use prospective observational trials, which stands to further corroborate current evidence regarding the efficacy and safety of currently-approved desmopressin formulations [ClinicalTrials.gov identifier: NCT043209975]. In the clinical setting, there exists significant investigative interest in phenotyping the population of patients most likely to respond to antidiuretic replacement therapy, including our own work on differential trajectories of intra-nocturnal urine production between distinct subsets of patients with nocturnal polyuria.

While desmopressin is the only antidiuretic peptide available to treat nocturia and other conditions characterized by AVP deficiency, several
alternative small-molecule AVP2R agonists are in various stages of development. A phase II trial of ASP7035 for nocturnal polyuria is listed in the European Clinical Trials Database as ongoing at some study sites (EudraCT2013-003701-25). Recently completed trials include a phase II study of SK-1404 for nocturnal polyuria [ClinicalTrials.gov identifier: NCT03116191] and a phase IIIB/III study of fedovapagon (VA106483) for nocturia in men with BPH [ClinicalTrials.gov identifier: NCT02637960]. While results of these trials are not widely available, a summary of key results was included in a prior evidence briefing on fedovapagon from the National Institute for Health Research, which reported significant improvement in primary study endpoints pooled across the entire treatment period.79 Even more recently, a series of newly discovered truncated AVP analogs were reported to retain AVP2R potency with increased selectivity, and thus hold the potential to further improve the pharmacological profile of antidiuretic replacement therapy.80 Two of these new compounds, FE 202217 and FE 201836, were selected for clinical development, and a response-adaptive dose-finding phase II trial in nocturnal polyuria patients has been completed for FE201836 [ClinicalTrials.gov identifier: NCT03201419].

Additional pharmacotherapies for nocturnal polyuria

While medications prototypically used for lower urinary tract dysfunction have been increasingly recognized to affect systems and processes beyond the bladder,81–83 their potential effects on physiologic fluid handling and urine production are highly complex.84–86 and possible benefit in reducing nocturnal urine production has not been consistently demonstrated.87–91 Further, these agents have been studied most extensively in carefully selected LUTS patient subsets, among which they generally reduce nocturia by 0.2−0.4 or fewer voids per night beyond placebo.71 As such, desmopressin remains the only medical therapy in the clinician’s standard toolkit for LUTS from which clinically meaningful improvement in nocturia due to nocturnal polyuria may be reasonably expected.

However, beyond antidiuretic replacement therapy, several other emerging pharmacotherapies may also be effective in targeting excess nocturnal urine production. At present, timed diuretic therapy holds a Grade C recommendation from the EAU guidelines panel for male LUTS, but does find support through Level 1B evidence.71 Evidence supporting the role of pharmacotherapy for hypertension, nonsteroidal anti-inflammatory drugs (NSAIDs), and sex hormone replacement therapy in treating nocturnal polyuria is variable in quality. Moreover, the specific physiologic mechanisms by which these agents contribute to a positive treatment response in patients with nocturia have not been completely characterized, but such knowledge gaps are the focal point of extensive ongoing nocturnal polyuria research.75,92 As was the case for antidiuretic replacement therapy, diuretic therapy for nocturia should be accompanied by regular screening for hyponatremia,71 while all above-mentioned modalities require careful patient selection and shared decision-making to optimize the balance between therapeutic effect and risks associated with treatment.93–96

Diuretics

The relationship between nocturia and diuretics is rather paradoxical and highly dependent on the specific situation at hand. Several population studies have identified an association between nocturia severity and diuretic use,97–99 and yet, multiple double-blind placebo-controlled trials involving healthy adults have found afternoon administration of potent diuretics to significantly improve nocturia. Because diuretics are a core tenet in the management of congestive heart failure and other volume overload states, and daytime third-space fluid sequestration, in and of itself, is an important pathophysiologic mechanism of nocturnal polyuria in some patients,100 the population-level association between nocturia and diuretics is likely explained, in large part, by the status of diuretics as a marker of volume overload states.101,102 In contrast, among otherwise healthy adults, administration of short-acting diuretics in the afternoon (i.e., more than 4–6 h prior to bedtime) is thought to improve nocturia by restoring the circadian rhythm of sodium homeostasis.103

In a double-blind randomized placebo-controlled crossover study, adults regularly experiencing ≥2 nocturnal voids in a general practice setting were administered 2 weeks of bumetanide 1 mg and of placebo, taken 4–6 h prior to bedtime.104 Of the 28 patients who completed the study, bumetanide conferred a significant benefit compared with placebo in median number of weekly nocturnal voids
(10.0 versus 13.8, p < 0.05). A total of 33 patients were initially enrolled in the study, including 2 excluded for nonadherence and 3 excluded for adverse events, although the time frame and severity of the adverse events was not made clear.

These results were later extended through the use of voiding diaries in a subsequent 4-week double-blind randomized placebo-controlled study of furosemide. Reynard et al. randomized 49 men ≥ 50 years with nocturnal polyuria to receive afternoon furosemide 40 mg or placebo following a 2-week placebo run-in period. Nighttime and daytime voiding frequency and voided volumes were compared between groups using 7-day voiding diaries completed in the second week of the run-in period and then during the fourth week of treatment. Of the 43 (88%) men who completed the study, furosemide conferred a significant benefit in nocturia frequency (−0.5 versus 0, p = 0.014) and the proportion of subjects responding by ≥ 1 nightly void (36.8% versus 5.0%, p = 0.02). While the change in nocturnal urine volume observed between groups was not statistically significant (−120 versus + 9 ml, p = 0.064), subjects in the experimental group found to experience a significant increase in daytime voided volume with no change in 24-h urine output, corresponding to a significant improvement in the nocturnal polyuria index with furosemide (−0.18 versus 0, p = 0.001). No adverse events were reported.

The efficacy of furosemide in treating nocturia has been also been assessed in two studies involving combination pharmacotherapy. One trial published in Chinese randomized 64 LUTS patients to receive afternoon furosemide 40 mg combined with doxazosin 4 mg or doxazosin monotherapy. Combination therapy conferred significant improvement in nocturia frequency (−1.22 versus − 0.47 voids, p = 0.003) and nocturnal urine volume (−138 versus − 43 ml, p < 0.001) relative to alpha-blocker monotherapy. In another prospective randomized control trial of adults ≥ 60 years with nocturia, afternoon furosemide staggered with bedtime desmopressin therapy was found to significantly improve nocturia severity compared with placebo, but it should be noted that loop diuretics remain a contraindication to desmopressin in current FDA prescriber guidelines.

A more recent multicenter open-label randomized crossover trial compared the efficacy of furosemide and an gosha-jinki-gan (GJG) – an East Asian blended herbal medicine which is popular in some countries for nocturia and other LUTS – in patients ≥ 50 years of age with nocturia (≥ 2 nightly voids) due to nocturnal polyuria. Furosemide 20 mg was administered once daily in the afternoon, while GJG 7.5 mg was administered 3 times daily, and patients sequentially received each treatment for a total of 4 weeks. Of the 36 patients who completed the study, analysis of 3-day voiding diaries revealed significant improvement in mean nocturnal voiding frequency with both interventions relative to baseline [3.3 with furosemide and 3.9 with GJG, compared with 4.4 voids at baseline (p < 0.001, p = 0.020, respectively)], as well as significantly greater benefit with furosemide compared with GJG (p < 0.001). Mean nocturnal urine volume was also lower with furosemide compared with GJG and baseline [793 ml with furosemide, 897 ml with GJG, and 991 ml at baseline (p < 0.001 between furosemide and both GJG and baseline)]. All adverse events were graded as mild and no serum electrolyte imbalances were observed.

**Antihypertensive therapy**

Disruption in the normal circadian rhythm of blood pressure has been increasingly recognized as an important mediator of the widely described population-level association between nocturia and hypertension. Blood pressure follows a well-defined circadian pattern, characterized by a 10–20% decline during the main sleeping period relative to daytime. The absence of this expected nocturnal blood pressure decline, or “dip,” is referred to as non-dipping hypertension – a phenomenon affecting upwards of 40–50% of hypertensive adults. In the Nagahama cohort study of community-dwelling adults in the Japanese general population, frequent nocturnal urination was found to be independently associated with a smaller drop in nocturnal blood pressure relative to daytime blood pressure, as determined from scheduled home blood pressure recordings. Similar results were observed using multi-day ambulatory blood pressure monitoring in the HEIJO-KYO cohort study of community-dwelling older adults in Japan, which found nocturia to be significantly associated with higher nighttime blood pressure and blunted nocturnal dipping, independent of several potential confounding variables including antihypertensive medication utilization and circadian rhythm parameters.
The pathophysiology of nocturia owing to non-dipping hypertension has not yet been fully characterized, but likely involves dysregulation of the renin-angiotensin-aldosterone pathway, corresponding to a relative excess in aldosterone and enhanced nocturnal natriuresis. In a well-controlled study of healthy Danish men with occasional nocturia, the occurrence of nocturia was characterized by both greater nocturnal urine volume and higher nighttime mean arterial blood pressure compared with nights without nocturia, supporting the role of excess nocturnal urine production as a key mediator in the relationship between nocturia and nocturnal blood pressure. Non-dipping hypertension on ambulatory blood pressure monitoring was also found to be significantly more prevalent in nocturic subjects with versus without nocturnal polyuria in a recent convenience sample of patients with LUTS.

Current evidence suggests that medical optimization of hypertensive disease may also be an effective intervention in the clinical management of nocturnal polyuria. In a prospective clinical study, Cho et al. reported significant improvement in nocturia frequency, nocturnal urine volume, and nocturnal polyuria index after 4 weeks of afternoon hydrochlorothiazide 25 mg adjunctive therapy in men with nocturia refractory to alpha blocker monotherapy. Although blood pressure was not taken into account, it should be noted that thiazide diuretics exert a particularly pronounced antihypertensive effect, as evidenced by the fact that thiazide-like diuretics are often warranted as first-line management for hypertension. In a non-controlled exploratory analysis of elderly patients (73.3% with nocturia) with losartan-refractory hypertension started on hydrochlorothiazide 12.5 mg adjunctive therapy in alpha blocker refractory to alpha blocker monotherapy. Although blood pressure was not taken into account, it should be noted that thiazide diuretics exert a particularly pronounced antihypertensive effect, as evidenced by the fact that thiazide-like diuretics are often warranted as first-line management for hypertension. In a non-controlled exploratory analysis of elderly patients (73.3% with nocturia) with losartan-refractory hypertension started on hydrochlorothiazide 12.5 mg adjunctive therapy in alpha blocker monotherapy.

More recently, Lee et al. published data from a 14-day multicenter phase II double-blind randomized placebo-controlled 4-arm parallel study of a novel immediate/sustained-release formulation of combination acetaminophen-ibuprofen pharmacotherapy [ClinicalTrials.gov identifier: NCT02646826]. A total of 86 patients with ≥2.5 nightly voids and overactive bladder symptoms were assigned one of three dose levels or placebo. The active medication conferred significant benefit in reducing average nocturnal voiding frequency compared with placebo at all dose levels [−1.1 with low-dose, −1.4 with mid-dose, and −1.3 with high-dose compared with −0.3 with placebo (p = 0.002, p = 0.003, p = 0.001, respectively)]. There were no adverse events deemed treatment-related or severe in any group.

Although both aforementioned studies were limited by the absence of voiding diary data to quantify changes in nocturnal urine production, extended-duration diaries were obtained through a 2-week double-blind randomized placebo-controlled crossover study of diclofenac. Addia et al. reported that diclofenac 50 mg tablets taken nightly by 26 adult patients with nocturia (≥2 nightly voids) due to nocturnal polyuria conferred significant benefit compared with placebo, with nocturia frequency improving from 2.7 to 2.3 voids (<0.004) and nocturnal polyuria index improving from 0.44 to 0.39 (<0.001), as well as borderline significance observed for nocturnal urine volume (802–745 ml, p = 0.05). Notably, the significant shift in 24-h urine production toward the daytime period (i.e., decreased nocturnal polyuria index) is consistent with well-controlled

Nonsteroidal anti-inflammatory drugs
NSAIDs inhibit the synthesis of prostaglandins, which are known to increase and maintain renal blood flow and subsequent sodium and water excretion, and may also indirectly counteract renal free water conservation via inhibition of endogenous AVP activity at the renal collecting duct. In a 1-month double-blind randomized placebo-controlled study, 80 men with ≥2 nocturnal voids and LUTS with BPH were assigned to receive nightly 100 mg celecoxib – a selective cyclooxygenase-2 inhibitor – or placebo. Patients in the exposure group experienced significant benefit in mean nocturnal voiding frequency, whereas no such effect was observed among controls [5.17–2.5 with celecoxib and 5.30–5.12 with placebo (p < 0.0001, p = 0.980, respectively)]. Four (10%) patients in the experimental group experienced mild gastric discomfort and no serious adverse events were reported in either group.
physiologic evidence on the effect of diclofenac on renal function, characterized by a rapid and persistent reduction in free water clearance owing to a 35% decrease in renal plasma flow and glomerular filtration rate with a nadir at 2 h and evidence of recovery starting at 3 h. Several institutional studies have also demonstrated efficacy in treating nocturia with loxoprofen, a non-selective cyclooxygenase inhibitor marketed in some countries, with evidence supporting reductions in nocturnal urine volume as the primary mediator of nocturia treatment response.

Hormone replacement therapy
During and after the transition to menopause, nocturia may arise in the context of the genitourinary syndrome of menopause (GSM), which is a broad symptom complex encompassing multiple lower urinary tract symptoms and genital/sexual signs and symptoms associated with a decrease in sex hormones. A wide range of pharmacologic treatment options are available for GSM, including multiple formulations of systemic and vaginal estrogen products, as well as newer non-estrogen medications such as the selective estrogen receptor modulator ospemifene. Evidence derived from patients with OABS and secondary analyses of pivotal trials on the systemic effects of estrogen replacement therapy identified a significant therapeutic benefit of hormone replacement therapy in improving nocturia severity. Retrospective data from postmenopausal women with symptoms consistent with OABS suggest that ospemifene may also be effective for treating nocturia.

Although the direct role of GSM pharmacotherapy in the management of nocturia has classically received relatively less attention, nocturia has recently been recognized not only as one potential facet of the GSM, but rather as one of the most pervasive complaints in this population. The direct relevance of nocturia in patients with GSM is also underscored by a recent prospective observational study of systemic hormone replacement therapy from Pauwaert and colleagues, which was highly novel in that it considered nocturia the primary outcome variable, and found oral estradiol-progesterone combination therapy to indeed confer significant benefit for nocturia. A prospective observational cohort study led by Pauwaert et al. to assess the effect of 10 different hormone replacement therapies on nocturia is also in the active recruitment phase (ClinicalTrials.gov identifier: NCT04433897).

Nocturnal polyuria is thought to be the most common cause of nocturia in patients of all ages and backgrounds, but its prevalence further increases with age, such that a disproportionate burden of nocturnal polyuria would be expected in postmenopausal women compared with younger nocturia cohorts. Consistently, exploratory data have identified decreased urine output as a potential central mechanism in nocturia treatment response following hormone replacement therapy in postmenopausal women. Well-controlled physiologic evidence demonstrates that administration of estradiol is associated with increased plasma AVP concentration, volume expansion, and a lower osmotic threshold for AVP release, as well as enhanced renal sodium reabsorption despite a stable plasma aldosterone concentration, suggesting that synthetic estrogens may also directly influence electrolyte handling at the level of the kidney. Taken together, current evidence suggests that estrogens as well as progestagens play an important role in the central regulation of whole-body fluid balance and sodium regulation. For an excellent review on the hormone changes and fluid regulation during menopause, see Stachenfeld.

Emerging technologies: individualizing nocturnal polyuria diagnosis and treatment
In recent years, the nocturia research community has grown increasingly aware of the extensive breadth of pathophysiologic mechanisms that may underlie nocturia. Parallel to the diversity in nocturia pathophysiology, nocturia patients are similarly heterogeneous with respect to the composition of urine produced during the hours of sleep. Compared with nocturia patients without nocturnal polyuria, the volume of urine produced during the night by those with nocturnal polyuria is not only greater in volume, but also significantly more dilute during the early hours of sleep. Consistently, our own analysis of the volume and osmolality of a single urine sample from the early hours of the night revealed that these parameters combined can predict a diagnosis of nocturnal polyuria with a reasonably high degree of sensitivity and specificity.

While the volume of a single void can be measured easily, urine osmolality – the gold standard parameter for quantifying urine concentration – was historically measured using a freezing point depression technique, which is time-intensive and not widely available in the routine diagnostic laboratory setting. However, urine osmolality was
recently demonstrated to be reliably estimated from an assessment of standard urinalysis parameters (e.g., creatinine, glucose, and specific gravity) in conjunction with urine conductivity – a dilution parameter which is relatively easy to obtain using meters that can now be integrated into standard urinalysis equipment. Accordingly, current technology now makes feasible the analysis of single-void nocturnal urine samples in a general diagnostic laboratory setting to obtain clinically meaningful data for diagnosing nocturnal polyuria. This potential diagnostic alternative is particularly noteworthy in view of growing investigative interest in adjunctive strategies to voiding diary analysis in order to facilitate a more patient-centered approach to nocturia evaluation and management.

Even among patients who share a common diagnosis nocturnal polyuria, the composition of their nocturnal urine is highly variable, such that most nocturnal polyuria patients can be further phenotyped as having (a) excess free water diuresis, (b) excess solute diuresis, or (c) mixed water/solute diuresis (Figure 1). Phenotyping patients by the composition of their excess urine volume – the relevant substrate for pharmacologic interventions directed at nocturnal polyuria – carries the potential to directly facilitate individualized treatment. For example, in view of the mechanism of antidiuretic replacement therapy, patients with nocturnal polyuria owing to water diuresis or a mixed phenotype would be expected to demonstrate the most robust response to treatment with desmopressin. Conversely, normalization of circadian homeostasis with appropriately timed diuretic/natriuretic would likely be of particular benefit in patients with a solute-predominant phenotype. Urine composition-based phenotyping may thus also be useful in guiding future research on antihypertensives, NSAIDs, and sex hormone replacement therapy in the treatment of nocturnal polyuria.

Beyond substrate-guided nocturnal polyuria phenotypes, contemporary advancements in our understanding of the pathogenesis of nocturnal polyuria, and AVP dysregulation in particular, have introduced several novel opportunities for point-of-care testing in patients with nocturnal polyuria. Urinary AVP from early-morning urine samples has been recognized as a potential biomarker for nocturnal polyuria, and, more specifically, impaired circadian rhythmicity in endogenous AVP activity. Additionally, pre-treatment plasma copeptin levels have been found to be predictive of desmopressin response in younger patients with nocturnal polyuria, and this concept is also the subject of a large ongoing prospective observational study currently in the recruitment phase [ClinicalTrials.gov identifier: NCT02621736]. Measurement of arginine-stimulated plasma copeptin has been identified as an effective and relatively safe alternative to the water deprivation test in the diagnosis of the polyuria-polydipsia syndrome, and it stands to
reason that this technology may also be relevant in identifying nocturnal polyuria owing to blunted nocturnal endogenous AVP activity.163

**Future directions**

In general, evidence supporting the efficacy and safety of non-antidiuretic therapies for nocturnal polyuria remains limited, and combination pharmacotherapies targeting excess nocturnal urine production have likewise not been well studied. Further research is also needed to better characterize the patients most likely to respond to anti-diuretic replacement therapy and other pharmacologic modalities targeting excess nocturnal urine production. While this narrative review highlights mechanisms underlying the effects of several medications on nocturnal urine production in particular, nocturia treatment response with medications other than diuretics has not been completely characterized, and these agents may also alter other factors relevant to nocturia such as bladder contractile function and sleep architecture.164–170 The utility of urinary phenotypes, as well as copeptin assays and other potential modalities for point-of-care testing, requires evaluation in larger study samples of real-world patients with nocturnal polyuria.

**Authors’ contributions**

Conceptualization, T.F.M. and A.J.W.; Investigation, T.F.M.; Writing – Original Draft, T.F.M.; Writing - Review & Editing, T.F.M., J.P.W., K.E. and A.J.W.

**Conflict of interest statement**

Thomas F. Monaghan has no direct or indirect commercial incentive associated with publishing this article and certifies that all conflicts of interest relevant to the subject matter discussed in the manuscript are the following: Jeffrey P. Weiss is a consultant for Ferring and the Institute for Bladder and Prostate Research, outside the submitted work. Karel Everaert is a consultant and lecturer for Medtronic and Ferring and reports institutional grants from Allergan, Ferring, Astellas, and Medtronic, outside the submitted work. Alan J. Wein has served as an advisor/consultant for Bulkamid, Medtronic, Serenity, Urovant, and Velicept, outside the submitted work.

**Funding**

The authors received no financial support for the research, authorship, and/or publication of this article.

**References**

1. Everaert K, Anderson P, Wood R, et al. Nocturia is more bothersome than daytime LUTS: results from an observational, real-life practice database including 8659 European and American LUTS patients. *Int J Clin Pract* 2018; 72: e13091.

2. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol* 2006; 50: 1306–1314; discussion 14–15.

3. Bliwise DL, Dijk DJ and Juul KV. Nocturia is associated with loss of deep sleep independently from sleep apnea. *Neurol Urodyn* 2015; 34: 392.

4. Pesonen JS, Cartwright R, Vernooij RWM, et al. The impact of nocturia on mortality: a systematic review and meta-analysis. *J Urol* 2020; 203: 486–495.

5. Pesonen JS, Vernooij RWM, Cartwright R, et al. The impact of nocturia on falls and fractures: a systematic review and meta-analysis. *J Urol* 2020; 203: 674–683.

6. Van Dijk MM, Wijkstra H, Debruyne FM, et al. The role of nocturia in the quality of life of men with lower urinary tract symptoms. *BJU Int* 2010; 105: 1141–1146.

7. Bliwise DL, Wagg A and Sand PK. Nocturia: a highly prevalent disorder with multifaceted consequences. *Urology* 2019; 133: 3–13.

8. Emeruwa CJ, Epstein MR, Michelson KP, et al. Prevalence of the nocturnal polyuria syndrome in men. *Neurol Urodyn* 2020; 39: 1732–1736.

9. Weiss JP, Blaivas JG, Bliwise DL, et al. The evaluation and treatment of nocturia: a consensus statement. *BJU Int* 2011; 108: 6–21.

10. Epstein M, Gerber JA, Weiss JP, et al. Nocturia: evaluation and management. *Curr Bladder Dysfunct Rep* 2017; 12: 95–103.

11. Malde S, Patel A, Martinez-Pineiro L, et al. Incidence of nocturia in men with lower urinary tract symptoms associated with benign prostatic enlargement and outcomes after medical treatment: results from the evolution European association of urology research foundation prospective multinational registry. *Eur Urol*
22. Lose G, Lalos O, Freeman RM, et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. *Am J Obstet Gynecol* 2003; 189: 1106–1113.

23. Mattiasson A, Abrams P, Van Kerrebroeck P, et al. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. *BJU Int* 2002; 89: 855–862.

24. Andersson KE, Longstreth J, Brucker BM, et al. Pharmacokinetic and pharmacodynamic properties of a micro-dose desmopressin (AV002) in healthy water-loaded subjects. *Pharm Res* 2019; 36: 92.

25. Eckford SD, Carter PG, Jackson SR, et al. An open, in-patient incremental safety and efficacy study of desmopressin in women with multiple sclerosis and nocturia. *Br J Urol* 1995; 76: 459–463.

26. Weiss JP. Nocturia: focus on etiology and consequences. *Rev Urol* 2012; 14: 48–55.

27. Juul KV, Malmberg A, van der Meulen E, et al. Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia. *BJU Int* 2017; 119: 776–784.

28. Lottmann H, Baydala L, Eggert P, et al. Long-term desmopressin response in primary nocturnal enuresis: open-label, multinational study. *Int J Clin Pract* 2009; 63: 35–45.

29. Wolfish NM, Barkin J, Gorodzinsky F, et al. The Canadian enuresis study and evaluation—short- and long-term safety and efficacy of an oral desmopressin preparation. *Scand J Urol Nephrol* 2003; 37: 22–27.

30. Djurhuus J, Matthiesen T and Rittig S. Similarities and dissimilarities between nocturnal enuresis in childhood and nocturia in adults. *BJU Int* 1999; 84: 9–12.

31. Goessaert AS, Everaert K, Hoebke P, et al. Nocturnal enuresis and nocturia, differences and similarities - lessons to learn? *Acta Clin Belg* 2015; 70: 81–86.

32. Moffatt ME, Harlos S, Kirshen AJ, et al. Desmopressin acetate and nocturnal enuresis: how much do we know? *Pediatrics* 1993; 92: 420–425.

33. Tikkinen KA, Johnson TM II, Tammela TL, et al. Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. *Eur Urol* 2010; 57: 488–496.

34. Weiss JP, Zinner NR, Klein BM, et al. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. *Neurolour* 2012; 31: 441–447.

35. Bing MH, Moller LA, Jennum P, et al. Prevalence and bother of nocturia, and causes...
of sleep interruption in a Danish population of men and women aged 60–80 years. BJU Int 2006; 98: 599–604.

36. Ohayon MM. Nocturnal awakenings and comorbid disorders in the American general population. J Psychiatr Res 2008; 43: 48–54.

37. Bliwise DL, Holm-Larsen T, Goble S, et al. Short time to first void is associated with lower whole-night sleep quality in nocturia patients. J Clin Sleep Med 2015; 11: 53–55.

38. Bes F, Schulz H, Navelet Y, et al. The distribution of slow-wave sleep across the night: a comparison for infants, children, and adults. Sleep 1991; 14: 5–12.

39. Carskadon MA and Dement WC. Normal human sleep: an overview. In: Kryger M, Roth T and Dement W (eds) Principles and practice of sleep medicine. 4th ed. Philadelphia, PA: Elsevier, Saunders, 2005; pp.13–23.

40. Bellesi M, Riedner BA, Garcia-Molina GN, et al. Enhancement of sleep slow waves: underlying mechanisms and practical consequences. Front Syst Neurosci 2014; 8: 208.

41. Dijk DJ. Regulation and functional correlates of slow wave sleep. J Clin Sleep Med 2009; 5(Suppl. 2): S6–S15.

42. Lentz MJ, Landis CA, Rothermel J, et al. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol 1999; 26: 1586–1592.

43. Bliwise DL, Holm-Larsen T and Goble S. Increases in duration of first uninterrupted sleep period are associated with improvements in PSQI-measured sleep quality. Sleep Med 2014; 15: 1270–1278.

44. Bliwise DL, Holm-Larsen T, Goble S, et al. Delay of first voiding episode is associated with longer reported sleep duration. Sleep Health 2015; 1: 211–213.

45. Juul KV, Jessen N, Bliwise DL, et al. Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels. Endocrine 2016; 53: 722–729.

46. Osterberg O, Savic RM, Karlsson MO, et al. Pharmacokinetics of desmopressin administered as an oral lysophosphate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol 2006; 46: 1204–1211.

47. Vande Walle JG, Bogaert GA, Mattsson S, et al. A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int 2006; 97: 603–609.

48. Yamaguchi O, Nishizawa O, Juul KV, et al. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial. BJU Int 2013; 111: 474–484.
58. Brucker BM. Nocturia: finding an identity. *Rev Urol* 2018; 20: 170–173.

59. Kaminetsky J, Fein S, Dmochowski R, et al. Efficacy and safety of SER120 nasal spray in patients with nocturia: pooled analysis of 2 randomized, double-blind, placebo controlled, phase 3 trials. *J Urol* 2018; 200: 604–611.

60. Weiss JP, Herschorn S, Albei CD, et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. *J Urol* 2013; 190: 965–972.

61. Sand PK, Dmochowski RR, Reddy J, et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. *J Urol* 2013; 190: 958–964.

62. Yamaguchi O, Juul KV, Falahati A, et al. Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program. *Low Urin Tract Symptoms* 2020; 12: 8–19.

63. Stachenfeld NS, Splenser AE, Calzone WL, et al. Sex differences in osmotic regulation of AVP and renal sodium handling. *J Appl Physiol* (1985) 2001; 91: 1893–1901.

64. Liu J, Sharma N, Zheng W, et al. Sex differences in vasopressin V2 receptor expression and vasopressin-induced antiurea. *Am J Physiol Renal Physiol* 2011; 300: F433–F440.

65. Stachenfeld NS, DiPietro L, Palter SF, et al. Estrogen influences osmotic secretion of AVP and body water balance in postmenopausal women. *Am J Physiol* 1998; 274: R187–R195.

66. Stachenfeld NS and Keefe DL. Estrogen effects on osmotic regulation of AVP and fluid balance. *Am J Physiol Endocrinol Metab* 2002; 283: E711–E721.

67. Juul KV, Andersson FL and Yamaguchi O. Achieving clinically meaningful quality of life benefits in nocturia takes time: results from a long-term, multicenter phase 3 study of desmopressin in Japanese patients. *Low Urin Tract Symptoms*. Epub ahead of print 10 September 2020. DOI: 10.1111/juts.12347.

68. Everaert K, Herve F, Bosch R, et al. International continence society consensus on the diagnosis and treatment of nocturia. *Neurourol Urodyn* 2019; 38: 478–498.

69. Gravas S, Cornu J, Gacci M, et al. Management of non-neurogenic male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Amhem: European Association of Urology, 2019.

70. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American geriatrics society 2019 updated AGS beers criteria® for potentially inappropriate medication use in older adults. *J Am Geriatr Soc* 2019; 67: 674–694.

71. Sakalis VI, Karavitakis M, Bedretdinova D, et al. Medical treatment of nocturia in men with lower urinary tract symptoms: systematic review by the European association of urology guidelines panel for male lower urinary tract symptoms. *Eur Urol* 2017; 72: 757–769.

72. Alwis US, Delanghe J, Dossche L, et al. Could evening dietary protein intake play a role in nocturnal polyuria? *J Clin Med* 2020; 9: 2532.

73. Denys MA, Decalf V, Kumps C, et al. Pathophysiology of nocturnal lower urinary tract symptoms in older patients with urinary incontinence. *Int J Urol* 2017; 24: 808–815.

74. Goessaert AS, Kröt L, Hoebeke P, et al. Diagnosing the pathophysiological mechanisms of nocturnal polyuria. *Eur Urol* 2015; 67: 283–288.

75. Hervé F, Abrams P, Bower W, et al. Is our current understanding and management of nocturia allowing improved care? International consultation on incontinence-research society 2018. *Neurourol Urodyn* 2019; 38(Suppl. 5): S127–S133.

76. Monaghan TF, Bliwise DL, Denys MA, et al. Phenotyping nocturnal polyuria: circadian and age-related variations in diuresis rate, free water clearance and sodium clearance. *Age Ageing* 2020; 49: 439–445.

77. Monaghan TF, Epstein MR, Bliwise DL, et al. Time of peak nocturnal diuresis rate between men with secondary nocturnal polyuria versus nocturnal polyuria syndrome. *Neurourol Urodyn* 2020; 39: 785–792.

78. Monaghan TF, Suss NR, Epstein MR, et al. Differential nocturnal diuresis rates among patients with and without nocturnal polyuria syndrome. *Eur Urol Focus* 2020; 6: 320–326.

79. Evidence Briefing: Fedovapagon for nocturia in men with benign prostatic hyperplasia. Newcastle, UK: National Institute for Health Research Innovation Observatory, http://www.io.nihr.ac.uk/report/fedovapagon-for-nocturia-in-men-with-benign-prostatic-hyperplasia/ (2018, accessed 15 October 2020)
80. Wiśniewski K, Qi S, Kraus J, et al. Discovery of potent, selective, and short-acting peptidic V₂ receptor agonists. *J Med Chem* 2019; 62: 4991–5005.

81. Andersson KE and Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. *Nat Clin Pract Urol* 2007; 4: 368–378.

82. Andersson KE and Van Kerrebroeck P. Pharmacotherapy for nocturia. *Curr Urol Rep* 2018; 19: 8.

83. Nitti VW. Is there a role for alpha-blockers for the treatment of voiding dysfunction unrelated to benign prostatic hyperplasia? *Rev Urol* 2005; 7(Suppl. 4): S49–S55.

84. Leonetti G. Effects of alpha-adrenoceptor blockers on renal function and blood pressure adjustment in human hypertension. *Drugs* 1988; 35(Suppl. 6): 53–59.

85. Procino G, Carmosino M, Milano S, et al. β3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function. *Kidney Int* 2016; 90: 555–567.

86. Yun JC, Oriji G, Gill JR Jr, et al. Role of muscarinic receptors in renal response to acetylcholine. *Am J Physiol* 1993; 265: F46–F52.

87. Kim YW, Park J, Chung H, et al. The effectiveness of silodosin for nocturnal polyuria in elderly men with benign prostatic hyperplasia: a multicenter study. *Int Neurourol J* 2015; 19: 190–196.

88. Koseoglu H, Aslan G, Ozdemir I, et al. Nocturnal polyuria in patients with lower urinary tract symptoms and response to alpha-blocker therapy. *Urology* 2006; 67: 1188–1192.

89. Kwon T, Oh TH, Choi S, et al. Influence of daytime or nighttime dosing with solifenacin for overactive bladder with nocturia: impact on nocturia and sleep quality. *J Korean Med Sci* 2017; 32: 1491–1495.

90. Rackley R, Weiss JP, Rovner ES, et al. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. *Urology* 2006; 67: 731–736; discussion 736.

91. Yokoyama O, Homma Y and Yamaguchi O. Imidafenacin, an antimuscarinic agent, improves nocturia and reduces nocturnal urine volume. *Urology* 2013; 82: 515–520.

92. Everaert K, Hervé F, Bower W, et al. How can we develop a more clinically useful and robust algorithm for diagnosing and treating nocturia? ICI-RS 2017. *Neurourol Urodyn* 2018; 37: S46–S59.

93. Butt DA and Harvey PJ. Benefits and risks of antihypertensive medications in the elderly. *J Intern Med* 2015; 278: 599–626.

94. Kagan R, Kellogg-Spadt S and Parish SJ. Practical treatment considerations in the management of genitourinary syndrome of menopause. *Drugs Aging* 2019; 36: 897–908.

95. Ong CKS, Lirk P, Tan CH, et al. An evidence-based update on nonsteroidal anti-inflammatory drugs. *Clin Med Res* 2007; 5: 19–34.

96. Sica DA. Diuretic-related side effects: development and treatment. *J Clin Hypertens (Greenwich)* 2004; 6: 532–540.

97. Asplund R. Nocturia in relation to sleep, somatic diseases and medical treatment in the elderly. *BJU Int* 2002; 90: 533–536.

98. Fitzgerald MP, Litman HJ, Link CL, et al. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey. *J Urol* 2007; 177: 1385–1389.

99. Johnson TM II, Sattin RW, Parmelee P, et al. Evaluating potentially modifiable risk factors for prevalent and incident nocturia in older adults. *J Am Geriatr Soc* 2005; 53: 1011–1016.

100. Torimoto K, Hirayama A, Samma S, et al. The relationship between nocturnal polyuria and the distribution of body fluid: assessment by bioelectric impedance analysis. *J Urol* 2009; 181: 219–224; discussion 24.

101. Monaghan TF, Gong F, Vaysblat M, et al. Nocturia: a marker of furosemide treatment response? An exploratory study. *BJU Int* 2020; 125: 636–637.

102. Weiss JP, Monaghan TF, Epstein MR, et al. Future considerations in nocturia and nocturnal polyuria. *Urology* 2019; 133s: 34–42.

103. Oelke M, De Wachter S, Drake MJ, et al. A practical approach to the management of nocturia. *Int J Clin Pract* 2017; 71: e13027.

104. Pedersen PA and Johansen PB. Prophylactic treatment of adult nocturia with bumetanide. *Br J Urol* 1988; 62: 145–147.

105. Reynard J. A novel therapy for nocturnal polyuria: a double-blind randomized trial of furosemide against placebo. *Br J Urol* 1998; 82: 932.

106. Huang SY, Zhu SX, Zeng BW, et al. [Furosemide plus doxazosin therapy for nocturia
in patients with BPH/LUTS]. Zhonghua Nan Ke Xue 2010; 16: 807–810.

107. Fu FG, Lavery HJ and Wu DL. Reducing nocturia in the elderly: a randomized placebo-controlled trial of staggered furosemide and desmopressin. Neurourology Urodyn 2011; 30: 312–316.

108. Yoshimura K, Shimizu Y, Masui K, et al. Furosemide versus Gosha-Jinki-Gan, a blended herbal medicine, for nocturnal polyuria: a randomized crossover trial. Low Urin Tract Symptoms 2012; 4: 77–81.

109. Markland AD, Vaughan CP, Johnson TM II, et al. Prevalence of nocturia in United States men: results from the national health and nutrition examination survey. J Urol 2011; 185: 998–1002.

110. Feldstein CA. Nocturia in arterial hypertension: a prevalent, underreported, and sometimes underestimated association. J Am Soc Hypertens 2013; 7: 75–84.

111. de la Sierra A, Redon J, Banegas JR, et al. Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension 2009; 53: 466–472.

112. Kanbay M, Turgut F, Uyar ME, et al. Causes and mechanisms of nondipping hypertension. Clin Exp Hypertens 2008; 30: 585–597.

113. Matsumoto T, Tabara Y, Murase K, et al. Nocturia and increase in nocturnal blood pressure: the Nagahama study. J Hypertens 2018; 36: 2185–2192.

114. Obayashi K, Saeki K and Kurumatani N. Quantitative association between nocturnal voiding frequency and objective sleep quality in the general elderly population: the HEIJO-KYO cohort. Sleep Med 2015; 16: 577–582.

115. Fujii T, Uzu T, Nishimura M, et al. Circadian rhythm of natriuresis is disturbed in nondipper type of essential hypertension. Am J Kidney Dis 1999; 33: 29–35.

116. Satoh M, Kikuya M, Ohkubo T, et al. Aldosterone-to-renin ratio and nocturnal blood pressure decline in a general population: the Ohasama study. J Hypertens 2011; 29: 1940–1947.

117. Graugaard-Jensen C, Rittig S and Djurhuus JC. Nocturia and circadian blood pressure profile in healthy elderly male volunteers. J Urol 2006; 176: 1034–1039; discussion 1039.

118. Takayama M, Omori S, Iwasaki K, et al. Relationship between nocturnal polyuria and non-dipping blood pressure in male patients with lower urinary tract symptoms. Low Urin Tract Symptoms 2019; 11: O98–O102.

119. Cho MC, Ku JH and Paick JS. Alpha-blocker plus diuretic combination therapy as second-line treatment for nocturia in men with LUTS: a pilot study. Urology 2009; 73: 549–553; discussion 54–55.

120. Unger T, Borghi C, Charchar F, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension 2020; 75: 1334–1357.

121. Kojima T, Akishita M, Iijima K, et al. Nocturia in elderly people with hypertension–no influence of low-dose thiazide added to losartan. J Am Geriatr Soc 2008; 56: 2155–2156.

122. Anderson RJ, Beri T, McDonald KM, et al. Prostaglandins: effects on blood pressure, renal blood flow, sodium and water excretion. Kidney Int 1976; 10: 205–215.

123. Kadokawa T, Hosoki K, Takeyama K, et al. Effects of nonsteroidal anti-inflammatory drugs (NSAID) on renal excretion of sodium and water, and on body fluid volume in rats. J Pharmacol Exp Ther 1979; 209: 219–224.

124. Falahatkar S, Mokhtari G, Pourreza F, et al. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology 2008; 72: 813–816.

125. Kinn AC, Elbarouni J, Seideman P, et al. The effect of diclofenac sodium on renal function. Scand J Urol Nephrol 1989; 23: 153–157.

126. Addla SK, Adeyoju AB, Neilson D, et al. Celecoxib for treatment of nocturia caused by overactive bladder: a multi-center, randomized, double blinded, placebo-controlled, 4-arm trial. Neurourology Urodyn 2019; 38: 740–748.

127. Lee KC, Rauscher F, Kaminesky J, et al. Novel immediate/sustained-release formulation of acetaminophen-ibuprofen combination (Paxerol®) for severe nocturia associated with overactive bladder: a randomized study of loxoprofen sodium 60 mg line treatment for nocturia in men with LUTS [BPH/LUTS]. Zhonghua Nan Ke Xue 2010; 16: 807–810.

128. Araki T, Yokoyama T and Kumon H. Anti-inflammatory drug for nocturia on patients with lower urinary tract symptoms. Low Urin Tract Symptoms 2019; 11: O98–O102.

129. Araki T, Yokoyama T, Araki M, et al. Novel immediate/sustained-release formulation of acetaminophen-ibuprofen combination (Paxerol®) for severe nocturia associated with overactive bladder: a multi-center, randomized, double blinded, placebo-controlled, 4-arm trial. Neurourology Urodyn 2019; 38: 740–748.

130. Lee KC, Rauscher F, Kaminesky J, et al. Novel immediate/sustained-release formulation of acetaminophen-ibuprofen combination (Paxerol®) for severe nocturia associated with overactive bladder: a multi-center, randomized, double blinded, placebo-controlled, 4-arm trial. Neurourology Urodyn 2019; 38: 740–748.
130. Okada S, Watanabe H, Kojima Y, et al. Loxoprofen sodium treatment for elderly men with refractory nocturia: effect on nighttime urine production. *Int J Urol* 2008; 15: 462–464.

131. Saito M, Kawatani M, Kinoshita Y, et al. Effectiveness of an anti-inflammatory drug, loxoprofen, for patients with nocturia. *Int J Urol* 2005; 12: 779–782.

132. Shin HI, Kim BH, Chang HS, et al. Long-term effect of loxoprofen sodium on nocturia in patients with benign prostatic hyperplasia. *Korean J Urol* 2011; 52: 265–268.

133. Srisukho S, Pantasri T, Piyamongkol W, et al. The experience of Genitourinary Syndrome of Menopause (GSM) among Thai postmenopausal women: the non-reporting issue. *Int Urogynecol J* 2019; 30: 1843–1847.

134. Portman DJ and Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American menopause society. *Menopause* 2014; 21: 1063–1068.

135. Cardozo L, Lose G, McClish D, et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. *Acta Obstet Gynecol Scand* 2004; 83: 892–897.

136. Kok AL, Burger CW, van de Weijer PH, et al. Micturition complaints in postmenopausal women treated with continuously combined hormone replacement therapy: a prospective study. *Maturitas* 1999; 31: 143–149.

137. Schiavi MC, Sciuca V, Giannini A, et al. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality? *Gynecol Endocrinol* 2018; 34: 666–669.

138. Schiavi MC, Zullo MA, Faiano P, et al. Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms. *Gynecol Endocrinol* 2017; 33: 942–945.

139. Pauwarter K, Goessaert A, Bruneel E, et al. Can hormonal replacement therapy be a solution for postmenopausal women with nocturia? *Eur Urol Open Sci* 2020; 19: e284.

140. Bruneel E, Maes H, Denys M-A, et al. Nocturia and hormone replacement therapy: do we change the bladder or the kidney? *ICS 2016; International Continence Society (ICS)*, 2016.

141. Stachenfeld NS. Hormonal changes during menopause and the impact on fluid regulation. *Reprod Sci* 2014; 21: 555–561.

142. Monaghan TF, Verbalis JG, Haddad R, et al. Diagnosing nocturnal polyuria from a single nocturnal urine sample. *Eur Urol Focus* 2020; 6: 738–744.

143. Oyaert M, Speeckaert MM and Delanghe JR. Estimated urinary osmolality based on combined urinalysis parameters: a critical evaluation. *Clin Chem Lab Med* 2019; 57: 1169–1176.

144. Nevêus T, Fonseca E, Franco I, et al. Management and treatment of nocturnal enuresis—an updated standardization document from the International Children’s Continence Society. *J Pediatr Urol* 2020; 16: 10–19.

145. Oyaert M and Delanghe J. Progress in automated urinalysis. *Ann Lab Med* 2019; 39: 15–22.

146. Blaivas JG, Weinberger JM, Weiss JP, et al. 1961 validation of an electronic bladder diary application. *J Urol* 2013; 189: e804–e805.

147. Bower WF, Rose GE, Ervin CF, et al. TANGO—a screening tool to identify comorbidities on the causal pathway of nocturia. *BJU Int* 2017; 119: 933–941.

148. Li ES, Poon MW, Manyevitch R, et al. A new paradigm for outpatient diagnosis and treatment of lower urinary tract symptoms utilizing a mobile app/software platform and remote and in-office visits: a feasibility study. *Urol Pract*. Epub ahead of print 28 April 2020. DOI: 10.1097/UPJ.0000000000000157.

149. Mateu Arrom L, Peri Cusi L, Lopez-Fando L, et al. Validation of a 3 day electronic bladder diary as an app for smart-phone. *Neurourol Urodyn* 2019; 38: 764–769.

150. Quinn P, Goka J and Richardson H. Assessment of an electronic daily diary in patients with overactive bladder. *BJU Int* 2003; 91: 647–652.

151. Sussman RD, Richter LA, Tefera E, et al. Utilizing technology in assessment of lower urinary tract symptoms: a randomized trial of electronic versus paper voiding diaries. *Female Pelvic Med Reconstr Surg* 2016; 22: 224–228.

152. Carter PG, Cannon A, McConnell AA, et al. Role of atrial natriuretic peptide in nocturnal polyuria in elderly males. *Eur Urol* 1999; 36: 213–220.

153. Sugaya K, Nishijima S, Oda M, et al. Biochemical and body composition analysis of
nocturia in the elderly. *Neurourol Urodyn* 2008; 27: 205–211.

154. Herek JI, FitzGerald MP, Mohindra M, et al. Solute and water excretion patterns in patients with nocturnal polyuria. *Nephro-Urol* 2010; 2: 526–531.

155. Denys MA, Kapila V, Weiss J, et al. Basic or extended urine sampling to analyse urine production? *Neurourol Urodyn* 2017; 36: 1867–1875.

156. Verbalis JG. Renal physiology of nocturia. *Neurourol Urodyn* 2014; 33(Suppl. 1): S6–S9.

157. Akiyama T, Hirayama A, Fujimoto K, et al. Cutoff value of urinary arginine vasopressin for nocturnal polyuria in elderly men. *Urology* 2007; 69: 98–102.

158. Hirayama A, Fujimoto K, Akiyama T, et al. Decrease in nocturnal urinary levels of arginine vasopressin in patients with nocturnal polyuria. *Urology* 2006; 68: 19–23.

159. Natsume O, Hashimura M, Matsushita C, et al. Preliminary experience with low-dose desmopressin treatment and urinary arginine vasopressin concentration as a response predictor for patients with nocturia with nocturnal polyuria. *Low Urin Tract Symptoms* 2014; 6: 107–112.

160. Hara T, Ohtomo Y, Endo A, et al. Evaluation of urinary aquaporin 2 and plasma copeptin as biomarkers of effectiveness of desmopressin acetate for the treatment of monosymptomatic nocturnal enuresis. *J Urol* 2017; 198: 921–927.

161. Fenske W, Refardt J, Chifu I, et al. A copeptin-based approach in the diagnosis of diabetes insipidus. *N Engl J Med* 2018; 379: 428–439.

162. Winzeler B, Cesana-Nigro N, Refardt J, et al. Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. *Lancet* 2019; 394: 587–595.

163. Monaghan TF, Bliwise DL and Wein AJ. Urinary symptoms: broadening the horizons for the copeptin assay. *J Endocrinol Invest* 2020; 43: 119–120.

164. Djavan B, Milani S, Davies J, et al. The impact of tamsulosin Oral Controlled Absorption System (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. *Eur Urol Suppl* 2005; 4: 61–68.

165. Hristov KL, Parajuli SP, Provence A, et al. Nongenomic modulation of the large conductance voltage- and Ca\(^{2+}\)-activated K\(^{+}\) channels by estrogen: a novel regulatory mechanism in human detrusor smooth muscle. *Physiol Rep* 2017; 5: e13351.

166. Huang ZL, Urate Y and Hayaishi O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. *Curr Opin Pharmacol* 2007; 7: 33–38.

167. Keefe DL, Watson R and Naftolin F. Hormone replacement therapy may alleviate sleep apnea in menopausal women: a pilot study. *Menopause* 1999; 6: 196–200.

168. Shahar E, Redline S, Young T, et al. Hormone replacement therapy and sleep-disordered breathing. *Am J Respir Crit Care Med* 2003; 167: 1186–1192.

169. Presicce F, Puccini F, De Nunzio C, et al. Variations of nighttime and daytime bladder capacity in patients with nocturia: implications for diagnosis and treatment. *J Urol* 2019; 201: 962–966.

170. Udo Y, Nakao M, Honjo H, et al. Analysis of nocturia with 24-h urine volume, nocturnal urine volume, nocturnal bladder capacity and length of sleep duration: concept for effective treatment modality. *BJU Int* 2011; 107: 791–798.